BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Formica V, Roselli M. Targeted therapy in first line treatment of RAS wild type colorectal cancer. World J Gastroenterol 2015; 21(10): 2871-2874 [PMID: 25780283 DOI: 10.3748/wjg.v21.i10.2871]
URL: https://www.wjgnet.com/1007-9327/full/v21/i10/2871.htm
Number Citing Articles
1
Elie Kassouf, Samer Tabchi, Mustapha Tehfe. Anti-EGFR Therapy for Metastatic Colorectal Cancer in the Era of Extended RAS Gene Mutational AnalysisBioDrugs 2016; 30(2): 95 doi: 10.1007/s40259-016-0166-5
2
Kristen K. Ciombor, Tanios Bekaii-Saab. A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal CancerThe Oncologist 2018; 23(1): 25 doi: 10.1634/theoncologist.2017-0203
3
Johnie Rose, Laura Homa, Chung Yin Kong, Gregory S. Cooper, Michael W. Kattan, Bridget O. Ermlich, Jeffrey P. Meyers, John N. Primrose, Sian A. Pugh, Bethany Shinkins, Uriel Kim, Neal J. Meropol. Development and validation of a model to predict outcomes of colon cancer surveillanceCancer Causes & Control 2019; 30(7): 767 doi: 10.1007/s10552-019-01187-x
4
Wen Tang, Lu Wang, Yan Liu, Dong Xiao. RasGRP Exacerbates Lipopolysaccharide-Induced Acute Kidney Injury Through Regulation of ERK ActivationOpen Forum Infectious Diseases 2022; 9(3) doi: 10.1093/ofid/ofac041
5
Haixing Wang, Dongxian Jiang, Qi Song, Chen Xu, Yuan Shi, Xiaojing Li, Jie Huang, Yifan Xu, Akesu Sujie, Haiying Zeng, Yunshi Zhong, Lijie Tan, Yingyong Hou. Prognostic impact and potential interaction of EGFR and c-Met in the progression of esophageal squamous cell carcinomaTumor Biology 2016; 37(7): 9771 doi: 10.1007/s13277-015-4692-4
6
Cristina Morelli, Vincenzo Formica, Silvia Riondino, Antonio Russo, Patrizia Ferroni, Fiorella Guadagni, Mario Roselli. Irinotecan or Oxaliplatin: Which is the First Move for the Mate?Current Medicinal Chemistry 2021; 28(16): 3158 doi: 10.2174/0929867327666201016124950
7
Aïssata Aimée Goïta, Dominique Guenot. Colorectal Cancer: The Contribution of CXCL12 and Its Receptors CXCR4 and CXCR7Cancers 2022; 14(7): 1810 doi: 10.3390/cancers14071810
8
Jiemin Zhao, Liangrong Shi, Mei Ji, Jun Wu, Changping Wu. The combination of systemic chemotherapy and local treatment may improve the survival of patients with unresectable metastatic colorectal cancerMolecular and Clinical Oncology 2017; 6(6): 856 doi: 10.3892/mco.2017.1247
9
Tony Ibrahim, Claude Saer-Ghorra, Vivane Trak-Smayra, Samah Nadiri, Charbel Yazbeck, Maria Baz, Joseph G. Kattan. Molecular characteristics of colorectal cancer in a Middle Eastern population in a single institutionAnnals of Saudi Medicine 2018; 38(4): 251 doi: 10.5144/0256-4947.2018.251
10
Vincenzo Formica, Francesco Sera, Chiara Cremolini, Silvia Riondino, Cristina Morelli, Hendrik-Tobias Arkenau, Mario Roselli. KRAS and BRAF Mutations in Stage II and III Colon Cancer: A Systematic Review and Meta-AnalysisJNCI: Journal of the National Cancer Institute 2022; 114(4): 517 doi: 10.1093/jnci/djab190
11
Mercedes Salgado Fernández, Maria Teresa Pérez Hoyos, Isabela Díaz de Corcuera, Alba Vidal Arbués, Marta García de la Torre. Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient programExpert Opinion on Drug Safety 2015; 14(8): 1171 doi: 10.1517/14740338.2015.1057495
12
Long Bai, Feng Wang, Zhe-zhen Li, Chao Ren, Dong-sheng Zhang, Qi Zhao, Yun-xin Lu, De-shen Wang, Huai-qiang Ju, Miao-zhen Qiu, Zhi-qiang Wang, Feng-hua Wang, Rui-hua Xu. Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancerMedicine 2016; 95(51): e4531 doi: 10.1097/MD.0000000000004531